Bank of New York Mellon Corp lessened its holdings in Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.4% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 742,551 shares of the medical device company’s stock after selling 10,681 shares during the period. Bank of New York Mellon Corp owned about 0.55% of Globus Medical worth $63,978,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Invesco Ltd. raised its position in Globus Medical by 1,235.2% in the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock worth $339,322,000 after acquiring an additional 3,595,339 shares during the period. Bank of Montreal Can boosted its stake in shares of Globus Medical by 15,317.1% during the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after acquiring an additional 3,351,380 shares during the last quarter. Sculptor Capital LP grew its position in shares of Globus Medical by 31.9% during the 2nd quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after acquiring an additional 667,850 shares during the period. Madison Avenue Partners LP grew its position in shares of Globus Medical by 3.0% during the 4th quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company’s stock valued at $229,167,000 after acquiring an additional 76,588 shares during the period. Finally, Alliancebernstein L.P. grew its position in shares of Globus Medical by 1,303.9% during the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after acquiring an additional 1,908,795 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.
Globus Medical Stock Performance GMED stock opened at $75.48 on Thursday. The company’s fifty day moving average price is $79.82 and its 200-day moving average price is $86.21. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The company has a market capitalization of $10.25 billion, a PE ratio of 17.55, a price-to-earnings-growth ratio of 1.57 and a beta of 0.95.
Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.
Insider Transactions at Globus Medical In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares in the company, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 18.38% of the stock is currently owned by insiders.
Analyst Ratings Changes A number of equities analysts recently commented on GMED shares. Needham & Company LLC raised their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Piper Sandler cut their price target on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a report on Monday, June 15th. Zacks Research cut Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Wells Fargo & Company decreased their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and an average target price of $103.75.
Check Out Our Latest Stock Analysis on GMED
Globus Medical Company Profile (Free Report)
Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.
In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.
Further Reading Five stocks we like better than Globus Medical Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFifth Third Bancorp Raises Position in Reynolds Consumer Products Inc. $REYN
NEXT HEADLINE »American Investment Services Inc. Decreases Holdings in Verizon Communications Inc. $VZ
Key Takeaways GMED grew first-quarter 2026 musculoskeletal sales 27%, with continued U.S. Spine momentum. Globus Medical ended the quarter debt-free with strong cash and operating cash flow supporting investments.GMED faces higher operating costs and foreign exchange swings that may affect near-term results. Globus Medical, Inc. (GMED - Free Report) is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories and unique surgical instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures. A solid financial health also adds to the stock’s appeal. Meanwhile, unfavorable foreign exchange and dull macro scenario remain concerns for GMED’s operations.
In the past year, this Zacks Rank #3 (Hold) stock has increased 43.5% against the industry's 10.2% decline. The S&P 500 composite has risen 21% in the same time frame.
The renowned medical device company has a market capitalization of $12.55 billion. Globus Medical has an earnings yield of 6.2% against the industry’s negative 3% yield. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 26.3%.
Let’s delve deeper.
Upsides for GMED StockMusculoskeletal Share Gains Continue: In the first quarter of 2026, the segment’s worldwide net sales rose 27% year over year, while base business sales, excluding Nevro, increased 13.2%. U.S. Spine marked its third straight quarter of 10% growth, with double-digit growth cited across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, posterior cervical and cervical plating.
Trauma revenues increased 30.4% in the quarter, helped by continued adoption of the core trauma line and the Precice limb lengthening portfolio, with ANTHEM Elbow continuing to exceed expectations, leading the company to ship additional sets to the field in the second quarter.
Financial Flexibility: Globus Medical ended the first quarter of 2026 with $560.9 million of cash and cash equivalents and $68.9 million of short-term marketable securities. The company remains debt-free, which preserves the capacity to fund R&D, sales-force investments and manufacturing expansion without relying on external financing. Liquidity is also being replenished internally, with $202.4 million of operating cash flow generated in the quarter. This supports continued capital spending and buybacks alongside ongoing integration work.
Image Source: Zacks Investment Research
What Ails GMED?Cost Inflation and Operating Spend Risk: The company operates in an environment of interest-rate uncertainty, inflation and geopolitical complexity that can disrupt supply chains and raise input costs. SG&A was $297.8 million in first-quarter 2026, or 39.2% of sales, up from $242.8 million a year earlier, reflecting higher compensation and benefit costs on higher volume. The company also recorded restructuring costs in the quarter as it continues synergy and integration plans, which could add variability to near-term expense trends.
Currency Exposure Persists: Globus Medical’s International net sales were $155 million in the first quarter of 2026, up 35.6% year over year as reported and 27.8% on a constant currency basis. This gap shows that foreign exchange can swing reported growth, even when underlying demand trends are steadier. The company recorded a $2.1 million foreign currency transaction loss in the quarter, which directly affected other income and expenses. With foreign revenues and expenses concentrated across regions such as Japan, the Eurozone, the United Kingdom and Australia, currency volatility can also affect gross margin and operating expense leverage over time.
Estimate TrendThe Zacks Consensus Estimate for GMED’s 2026 earnings per share (EPS) has remained unchanged at $4.74 in the past 30 days.
The consensus estimate for the company’s 2026 revenues is pegged at $3.20 billion, indicating an 8.7% rise from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Alcon (ALC - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Alcon has an earnings yield of 5.1% against the industry’s negative 2.8% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. ALC’s earnings topped estimates in three of the trailing four quarters and missed in one, the average surprise being 3.7%.
ALC carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers. Medical device companies operate within a unique ecosystem and are often easy to overlook. The fact that these firms have unique business models, revenue drivers, and innovation cycles may make them appealing as a supplement—or even an alternative—to better-known corners of the health care space.
Investors seeking the advantages of companies that don't depend on the approval of blockbuster drugs, can more easily make incremental innovations, or can derive revenue from recurring procedures, may want to consider the companies below. These and other similar firms stand to benefit from growing specialized demand for procedures such as spine surgery, sleep apnea treatment, and stroke treatment.
Get Globus Medical alerts:
Globus Grows Its Product Lineup and Revenue FollowsGlobus Medical Today
$76.68 -0.33 (-0.42%)
As of 11:01 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$51.79▼
$101.40P/E Ratio17.83
Price Target$103.75
Globus Medical, Inc. NYSE: GMED is an $11-billion firm designing and building implantable devices and surgical instruments used to treat spinal disorders. The firm has been quietly thriving thanks to strong organic revenue growth and margin improvements: in Q1 2026, for instance, revenue grew by 27% year over year (YOY) to nearly $760 million and earnings per share (EPS) climbed to $1.12 from 68 cents. Both of these figures were solidly above analyst expectations.
Management credits the growth to improving market share, operational discipline, stronger free cash flow, and the introduction of dozens of new products. The company's U.S. business in particular is thriving, having seen three consecutive quarters of at least 10% growth, but its international segment and enabling technologies business are also growing.
The company's products are widely favored and gaining additional traction thanks to Globus' strong sales approach, and it continues to receive new clearances from the FDA to expand its lineup. This has allowed the firm to raise its full-year EPS guidance by 30 cents to a range of $4.70-$4.80.
Despite these positive attributes, shares of GMED have slumped by about 7% year to date (YTD), though analysts expect a reversal and upside potential of nearly 29%. More than two-thirds of the 16 ratings for GMED are Buys.
Inspire's Fundamentals Are Strong, Despite Near-Term HeadwindsInspire Medical Systems Today
INSP
Inspire Medical Systems
$51.59 +0.99 (+1.95%)
As of 11:02 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$38.91▼
$147.03P/E Ratio11.45
Price Target$81.26
Nearly a third of U.S. adults over the age of 20 have obstructive sleep apnea (OSA), giving Inspire Medical Systems Inc. NYSE: INSP more than 80 million potential domestic customers. The company makes implantable neurostimulation devices to treat OSA. These devices are rapidly becoming a popular alternative to traditional continuous positive airway pressure (CPAP) options.
Still, INSP shares have experienced a major sell-off so far this year, falling by 44% YTD. The likely reason for this is the company's recent revenue slowdown: in the latest quarter, revenue climbed by under 2% YOY and management cut full-year sales guidance to between $825 million and $875 million as a result of prior-authorization delays.
The key consideration for investors is that these delays are not a fundamental reflection of weakness in Inspire's products, but a temporary slowdown in procedures due to external headwinds. Strong trial results for new products and improvements to adjusted EBITDA margin, operating cash flow, and more all point to the likelihood that momentum will pick up again. Analysts even see earnings growing by a massive 54% in the coming year.
This means that investors willing to wait out the current challenges may find INSP shares at a relative bargain based on a price-to-earnings (P/E) ratio of 11.4. The stock has 59% upside, even as analysts are somewhat hesitant given the current environment, assigning a Hold rating overall.
Earnings Challenges Linger, But Penumbra's New Study Could Be TransformativePenumbra Today
$318.36 +0.04 (+0.01%)
As of 11:02 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$221.26▼
$362.41P/E Ratio73.31
Price Target$360.33
Penumbra Inc. NYSE: PEN creates products to improve outcomes after strokes, aneurysms, and related medical events. After a share price spike early in the year, PEN stock has been gradually declining, though it remains up modestly YTD as of mid-July. The company's financials show some important strengths, including almost 16% YOY growth in revenue in Q1 2026, driven by global embolization and access gains. Gross profit margin is also expanding, having climbed by 1% YOY to 67.6% for the quarter.
At the same time, the company faces challenges, including a sizable earnings miss and a one-cent YOY decline in EPS last quarter. It's understandable, then, that analysts would be somewhat cautious: PEN receives a Hold rating overall, despite the most recent analyst rating being an enthusiastic reiterated Outperform by Evercore. This could be due to the company's upcoming FORWARD study, which aims to collect data on mechanical thrombectomy in the management of acute ischemic stroke. This is a promising avenue and one in which Penumbra has a distinct advantage over competitors.
Should You Invest $1,000 in Globus Medical Right Now?Before you consider Globus Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.
While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Key Takeaways GMED gained 43.6% in a year, outperforming its industry and the S&P 500 on strong business momentum. GMED saw U.S. Spine and Enabling Technologies growth, with Enabling Technologies revenues up 21.1%. GMED remains debt-free with strong operating cash flow, despite higher SG&A and currency headwinds. Globus Medical (GMED - Free Report) shares have surged 43.6% over the past year, showing impressive momentum. It has significantly outperformed the industry’s 6.5% decline and the S&P 500 composite’s 23.8% gain.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Based in Audubon, PA, Globus Medical develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company has two major product categories — Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions primarily consists of implantable devices, biologics, accessories and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Enabling Technologies is an advanced computer-assisted intelligent system that’s designed to enhance surgeons’ capabilities and streamline complicated surgical procedures for both patients and caregivers.
Key Catalysts for GMED’s GrowthGlobus Medical’s share price is trending upward, prompted by strong prospects in both the reporting segments. Within the Musculoskeletal arm, in the first quarter, U.S. Spine business marked its third straight quarter of 10% growth, with double-digit growth cited across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anteriorlumbar interbody fusion, posterior cervical and cervical plating. Trauma revenue growth was driven by continued adoption of the core trauma portfolio and the Precice limb-lengthening portfolio, while the ANTHEM Elbow system continued to exceed expectations.
Within the Enabling Technologies arm, ExcelsiusGPS platform continues to support implant pull-through and cross-selling as surgeons adopt a more integrated workflow. The company also carries out continued deal activity with a mix shift toward leases and rentals versus outright sales. In the first quarter, Enabling Technologies’ revenues increased 21.1% year over year.
Investors are also impressed with its investment in R&D and product cadence, which acts as a core part of its competitive positioning. Consistent with this strategy, first-quarter R&D expenses accounted for 4.8% of sales. Management expects R&D spending to reach 5% to 6% of net sales for the full year, with investments increasing methodically as product development efforts progress.
The company’s early second-quarter FDA 510(k) clearances for patient-specific lumbar spacers and rods further support its strategy of integrating planning software, enabling technologies, and implants into a unified workflow, a move that could strengthen account relationships and increase procedure-level pull-through over time.
Globus Medical ended the first quarter of 2026 with $560.9 million of cash and cash equivalents and $68.9 million of short-term marketable securities. The company remains debt-free. Liquidity is also being replenished internally, with $202.4 million of operating cash flow generated in the quarter. This supports continued capital spending and buybacks alongside ongoing integration work.
Image Source: Zacks Investment Research
Factors That May Offset GMED’s GainsThe company operates in an environment of interest-rate uncertainty, inflation and geopolitical complexity that can disrupt supply chains and raise input costs. SG&A was $297.8 million in first-quarter 2026, or 39.2% of sales, up from $242.8 million a year earlier, reflecting higher compensation and benefit costs on higher volume.
Additionally, Globus Medical recorded a $2.1 million foreign currency transaction loss in the first quarter, which directly affected other income and expenses. With foreign revenues and expenses concentrated across regions such as Japan, the Eurozone, the United Kingdom and Australia, currency volatility can also affect gross margin and operating expense leverage over time.
A Glance at GMED’s EstimatesIn the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained unchanged at $4.74.
Revenues are projected to grow 8.7% to $3.20 billion in 2026, while the same for 2027 is expected to reach $3.41 billion (up 6.6%).
Key PicksSome better-ranked stocks in the broader medical space are Alcon (ALC - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Alcon has an earnings yield of 5.1% against the industry’s negative 2.8% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. ALC’s earnings topped estimates in three of the trailing four quarters and missed in one, the average surprise being 3.7%.
ALC carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NYSE: GMED) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
If you are a long-term GMED stockholder please contact Justin Kuehn, Esq. by email at [email protected], or call (833) 672-0814. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2026 after the market close on Thursday, August 6, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events-webcasts.
To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
The audio archive will be available after the call on the Investors page of the Globus Medical website.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company”, “Globus”, “Globus Medical”, “we”, “us”, and “our” refers to Globus Medical, Inc.
Contact
Brian Kearns
Senior Vice President, Corporate Development and Investor Relations
(610) 930-1800 [email protected]
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Globus Medical (GMED - Free Report) Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across 65 counties worldwide and sells through a mix of direct sales representatives and independent distributors.
GMED is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.59; value investors should take notice.
One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.08 to $4.74 per share. GMED also boasts an average earnings surprise of +26.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, GMED should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Globus Medical (GMED - Free Report) Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across 65 counties worldwide and sells through a mix of direct sales representatives and independent distributors.
GMED is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. GMED has a Momentum Style Score of B, and shares are up 1% over the past four weeks.
For fiscal 2026, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.28 to $4.74 per share. GMED boasts an average earnings surprise of +26.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, GMED should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Globus Medical (GMED - Free Report) Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across 65 counties worldwide and sells through a mix of direct sales representatives and independent distributors.
GMED is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 17.86; value investors should take notice.
Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.28 to $4.74 per share. GMED boasts an average earnings surprise of +26.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, GMED should be on investors' short list.
Globus Medical (GMED) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Key Takeaways Globus Medical faces inflation, geopolitical and rate uncertainty that can disrupt supply chains. Globus Medical saw SG&A rise and incurred restructuring costs tied to integration efforts. Globus Medical posted a $2.1M FX loss despite strong international sales growth in Q1 2026. Globus Medical (GMED - Free Report) operates in a challenging environment caused by interest rate uncertainty, inflation and geopolitical tensions, which can disrupt supply chains and increase costs. While gross margin improved to 69.2% in the first quarter of 2026, it remains below management’s long-term target of the mid-70% range, leaving limited room to absorb higher costs.
Selling, general and administrative expenses rose to $297.8 million from $242.8 million a year earlier, mainly due to higher compensation and benefit costs associated with increased sales volume. The company also incurred restructuring expenses as it continues integration and synergy initiatives, which could lead to fluctuations in near-term operating costs.
Globus Medical’s international business adds another source of uncertainty. International net sales reached $155.0 million in the first quarter of 2026, increasing 35.6% year over year on a reported basis and 27.8% on a constant currency basis, highlighting the impact of exchange rate movements on reported results.
The company recorded a $2.1 million foreign currency transaction loss during the quarter, which reduced other income. With significant operations in regions such as Japan, the Eurozone, the United Kingdom and Australia, ongoing currency fluctuations could continue to affect revenue growth, profit margins and operating expenses over time.
Peer UpdateMedtronic’s (MDT - Free Report) operations remain vulnerable to cost inflation, reimbursement constraints, geopolitical disruption and changing global trade policies. It also embedded a roughly 1-point EPS drag from higher fuel and transportation costs tied to the recent shift in the geopolitical environment.
Medtronic generates a large portion of sales internationally, leaving reported results sensitive to exchange rates. Foreign exchange added $819 million to fiscal 2026 revenues, but fiscal 2027 guidance assumes a neutral to $100 million revenue drag.
Edwards Lifesciences’ (EW - Free Report) extensive global operations and overseas manufacturing facilities and suppliers bring certain financial, economic, political and other risks. The business is also currently experiencing staffing shortages within the hospital systems.
In the first quarter of 2026, these issues resulted in a 20.2% increase in COGS and a year-over-year decline of 64 basis points in gross margin. Foreign exchange is a major headwind for Edwards due to a considerable percentage of its revenues coming from outside the United States. Foreign exchange rates negatively impacted the second quarter gross profit margin by 60 basis points compared to the prior year.
GMED’s Stock Price PerformanceOver the past year, GMED shares have surged 37.1%, outperforming the industry’s 4.6% decline.
Image Source: Zacks Investment Research
GMED’s ValuationGMED currently trades at a forward 12-month price-to-sales (P/S) of 3.26X compared with the industry median of 4.49X.
Image Source: Zacks Investment Research
GMED Stock Estimate TrendIn the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
Image Source: Zacks Investment Research
GMED currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED - Free Report) or Penumbra (PEN - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Globus Medical and Penumbra are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that GMED is likely seeing its earnings outlook improve to a greater extent. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
GMED currently has a forward P/E ratio of 16.72, while PEN has a forward P/E of 62.44. We also note that GMED has a PEG ratio of 1.63. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. PEN currently has a PEG ratio of 1.94.
Another notable valuation metric for GMED is its P/B ratio of 2.27. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, PEN has a P/B of 8.47.
These are just a few of the metrics contributing to GMED's Value grade of B and PEN's Value grade of D.
GMED is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that GMED is likely the superior value option right now.
Key Takeaways GMED launched new elbow, navigation, drill and AMS implant products to expand its portfolio. GMED's R&D was 4.8% of Q1 2026 sales; full-year spending is expected at 5-6% of net sales. Globus Medical gained FDA clearances for patient-specific lumbar spacers and rods in Q2. Globus Medical (GMED - Free Report) continues to invest in research and development (R&D) and product cadence as a core part of its competitive positioning. Per the company, its team-oriented approach, active surgeon input and demonstrated capabilities position it to maintain a rapid rate of product launches.
In 2025, the company launched ANTHEM Elbow Fracture System, a fully comprehensive plating portfolio designed to address a wide spectrum of elbow fractures. The company also launched DuraPro with Navigation, a next-generation, oscillating system designed to safeguard delicate tissue. In addition to DuraPro, it launched Verzera, a navigated high-speed drill system integrated with the ExcelsiusGPS and ExcelsiusHub system. In addition, Globus Medical expanded the Advanced Materials Science (“AMS”) implant portfolio with the COHERE ALIF Spacer.
In the first quarter of 2026, R&D expenses were 4.8% of sales, with management expecting it to be 5-6% of net sales for the full year, with spend ramping methodically through the year as product efforts progress.
The company’s early second-quarter FDA 510(k) clearances for patient-specific lumbar spacers and rods also reinforce its roadmap to link planning software, enabling technologies, and implants into a single workflow, which can deepen account relationships and increase procedure-level pull-through over time. This launch activity complements the broader post-merger strategy of compressing development timelines and keeping the portfolio fresh across spine and orthopedics.
Peer UpdateTeleflex’s (TFX - Free Report) product development activity also remains robust. Recent additions include the AC3 range Intra-Aortic Balloon Pump, which received FDA 510(k) clearance in 2025 for patient transport use. Another addition is the Ringer Perfusion Balloon Catheter, which received FDA breakthrough device designation and is supported by an IDE study as it advances toward a coronary perforation indication. In emergency medicine, QuikClot Control+ gained FDA clearance for all grades of internal and external bleeding, expanding its potential use cases.
Thermo Fisher Scientific’s (TMO - Free Report) recent product launches include the PPD CorEvitas Chronic Hand Eczema Registry, a cohort registry designed to generate real-world evidence on patients being treated for chronic hand eczema in routine clinical care and Gibco CTS DynaXS Single Use Bioreactor, designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness.
GMED’s Stock Price PerformanceOver the past year, GMED shares have surged 34.2%, outperforming the industry’s 3.6% decline.
Image Source: Zacks Investment Research
GMED’s ValuationGMED currently trades at a forward 12-month price-to-sales (P/S) of 3.31X compared with the industry median of 4.50X.
Image Source: Zacks Investment Research
GMED Stock Estimate TrendIn the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
Image Source: Zacks Investment Research
GMED currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical (GMED - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 13.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
Why GMED Could Bounce Back Before LongThe heavy selling of GMED shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 27.24. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.
This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering GMED in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 6.3% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, GMED currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.
In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.
However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.
Our proprietary system currently recommends Globus Medical (GMED - Free Report) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.
Studies have shown that stocks with the best growth features consistently outperform the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy).
While there are numerous reasons why the stock of this medical device company is a great growth pick right now, we have highlighted three of the most important factors below:
Earnings GrowthEarnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for Globus Medical is 17%, investors should actually focus on the projected growth. The company's EPS is expected to grow 17% this year, crushing the industry average, which calls for EPS growth of 12.3%.
Impressive Asset Utilization RatioGrowth investors often overlook asset utilization ratio, also known as sales-to-total-assets (S/TA) ratio, but it is an important feature of a real growth stock. This metric shows how efficiently a firm is utilizing its assets to generate sales.
Right now, Globus Medical has an S/TA ratio of 0.6, which means that the company gets $0.6 in sales for each dollar in assets. Comparing this to the industry average of 0.59, it can be said that the company is more efficient.
While the level of efficiency in generating sales matters a lot, so does the sales growth of a company. And Globus Medical looks attractive from a sales growth perspective as well. The company's sales are expected to grow 8.4% this year versus the industry average of 5.9%.
Promising Earnings Estimate RevisionsBeyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for Globus Medical have been revising upward. The Zacks Consensus Estimate for the current year has surged 6.3% over the past month.
Bottom LineWhile the overall earnings estimate revisions have made Globus Medical a Zacks Rank #1 stock, it has earned itself a Growth Score of B based on a number of factors, including the ones discussed above.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination indicates that Globus Medical is a potential outperformer and a solid choice for growth investors.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Globus Medical (GMED - Free Report) Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across 65 counties worldwide.
GMED is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 17.16; value investors should take notice.
Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.21 to $4.66 per share. GMED also boasts an average earnings surprise of +26.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, GMED should be on investors' short list.
Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED - Free Report) and SONOVA HOLDING (SONVY - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Currently, Globus Medical has a Zacks Rank of #2 (Buy), while SONOVA HOLDING has a Zacks Rank of #4 (Sell). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that GMED is likely seeing its earnings outlook improve to a greater extent. But this is just one factor that value investors are interested in.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
GMED currently has a forward P/E ratio of 17.16, while SONVY has a forward P/E of 18.33. We also note that GMED has a PEG ratio of 1.68. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. SONVY currently has a PEG ratio of 3.73.
Another notable valuation metric for GMED is its P/B ratio of 2.29. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, SONVY has a P/B of 4.9.
These are just a few of the metrics contributing to GMED's Value grade of B and SONVY's Value grade of C.
GMED is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that GMED is likely the superior value option right now.
On May 20, 2026, Globus Medical Inc GMED shares rose 5.1% today, reaching a current price of $84.03. The stock is trading within a 52-week range of $51.79 to $101.40.
GF Value™ verdict: Current price of $84.03 is 14.6% below GF Value™ of $98.34.GF Score™ of 97/100 indicates a strong overall financial health and performance.Notable signal: Insider activity shows $1.9M in sales over the last three months with no buying. Is GMED Overvalued or Undervalued? The current price of Globus Medical Inc GMED at $84.03 is 14.6% below its GF Value™ estimate of $98.34, suggesting that the stock is undervalued. This creates a margin of safety for potential investors, as the GF Value™ assessment indicates a fair value that significantly exceeds the current trading price. The GF Valuation label marks GMED as "Modestly Undervalued," which signals a potential opportunity for growth. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the undervaluation presents an opportunity, it is essential to consider the risks associated with investing in a stock that has seen recent insider selling activity of $1.9M, which could suggest a lack of confidence among insiders. Overall, the combination of a strong GF Score™ and the undervalued status implies that GMED may have growth potential, but investors should proceed with caution given the insider selling trend.
How Does GMED's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)19.5x43.3x Forward P/E18.4xN/A GMED's current P/E (TTM) of 19.5x is significantly below its 5-year median P/E of 43.3x, indicating that the stock is trading at a much lower valuation compared to its historical performance. The forward P/E of 18.4x further supports the notion that the stock is reasonably priced relative to future earnings expectations. This P/E analysis aligns with the GF Value™ verdict of the stock being undervalued, as it suggests that the market has not fully recognized GMED's earnings potential.
What Does GMED's GF Score™ Tell Us? MetricRating GF Score™97/100 Financial Strength8/10 Profitability9/10 Growth10/10 Valuation8/10 Momentum10/10 The GF Score™ of 97/100 indicates that Globus Medical possesses strong financial health and performance across several key metrics. The highest scores are in Growth (10/10) and Momentum (10/10), reflecting the company’s robust business expansion and positive price trends. However, while the Financial Strength (8/10) and Valuation (8/10) rankings are also solid, they suggest areas where improvements could enhance overall stability. Overall, GMED shows a promising outlook with strong growth potential, but investors should be aware of the moderate financial strength compared to its growth capabilities.
What Are Insiders Doing with GMED Stock? Recent insider activity at Globus Medical indicates a selling trend, with insiders having sold $1.9M worth of shares over the past three months and no buying activity reported. This pattern may suggest a cautious outlook among insiders regarding the stock's near-term performance. While insider selling does not inherently indicate a negative outlook for the company, it can be a signal of potential uncertainty, particularly when combined with the stock's recent price fluctuations.
What This Means for Investors Based on the GF Value™ assessment, Globus Medical Inc GMED is currently undervalued, presenting a potential opportunity for growth. However, the recent insider selling could signal caution, and investors should weigh this factor alongside the stock's strong financial metrics.
For the complete analysis, visit the Globus Medical Inc GMED stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is GMED's GF Score™?
GMED has a GF Score™ of 97/100, indicating strong overall financial health and performance, suggesting a potential for higher long-term returns.
Is GMED overvalued or undervalued?
GMED is currently undervalued, with a GF Value™ estimate of $98.34 compared to its current price of $84.03, representing a 14.6% upside.
What is GMED's P/E ratio?
GMED's P/E (TTM) is 19.5x, which is significantly below its 5-year median P/E of 43.3x, indicating the stock is trading at a lower valuation compared to its historical performance.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Over the past several months, generative AI (GenAI) in the Medical Instruments industry has moved from experimental to operational use. Applications include generating synthetic medical images, simulating disease progression, creating potential drug molecules and simulatingtheir effects, to accelerate the long and costly drug development process. McKinsey’s latest survey of US healthcare leaders highlights several signals of gen AI’s maturation, with about 50% already implementing it across their organizations and more than 80% having deployed their first use cases to end users.
At the same time, regulatory bodies worldwide are adapting to this shift. The European Union AI Act (EU AI Act) 2024 introduced strict requirements for high-risk AI systems, such as AI-based medical software, including risk-mitigation systems, high-quality data sets and clear user information. As of 2025-end, the FDA’s AI/ML-Enabled Medical Devices list includes a cumulative total of more than 1400 devices, satisfying the applicable premarket requirements.
Grand View Research estimates the global AI in the healthcare market to expand at a CAGR of 38.9% from 2026 to 2033, building on a $36.67 billion valuation in 2025. Amid industry wide challenges, companies like Electromed (ELMD - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) appear well-positioned to thrive.
Industry Description The Zacks Medical - Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. This FDA-regulated sector encompasses a vast array of products, from transcatheter valves and orthopedic devices to advanced imaging equipment and robotics. Recent trends highlight the integration of AI in diagnostics, the expansion of telemedicine, the rise of robotic-assisted surgeries and developments in 3D printing, continuous glucose monitoring systems and gene editing. The rise of GenAI is also reshaping MedTech, from speeding up patient recruitment to optimizing trial designs and improving regulatory processes. The FDA’s Total Product Life Cycle approach supports faster development of safe and effective medical devices critical to public health.
3 Trends Shaping the Future of the Medical Instruments Industry GenAI Revolution: Over the past couple of years, there has been a significant increase in the adoption of GenAI within the medical instrument space, with hyper-personalization being the primary feature of GenAI-driven treatment options. GenAI, while analyzing vast and complex genetic and molecular data, is expected to help healthcare reach new heights in terms of predictive treatment options and smart hospital systems. According to Towards Healthcare, global GenAI in the healthcare market is projected to expand at a CAGR of 35.1% between 2026 and 2035, from a value of $2.65billion in 2025. Growth is being driven by rising demand for AI solutions in the healthcare industry, increasing investments and strategic partnerships between healthcare institutions and AI technology providers, as well as demand for precise and personalized treatment plans. The application of AI in the diagnostics space is growing enormously, with the market expected to witness a CAGR of 46.1% by 2034.
M&A Trend: The medical instrument space has been benefiting from the ongoing merger and acquisition (M&A) trend. It is a known fact that smaller and mid-sized industry players attempt to compete with the big shots through consolidation. The big players attempt to enter new markets through a niche product. According to a J.P. Morgan April 2026 report, medtech M&A activity in 2025 was highly concentrated, with large transactions accounting for the majority of value. At the same time, underlying deal volume remained more stable. Notable transactions in the fourth quarter include Abbott’s acquisition of Exact Sciences for $23 billion and Blackstone and TPG’s take-private deal of Hologic for $18 billion. The insight also states that medtech deal activity totaled $26.6 billion across 38 deals in the first quarter of 2026, including Boston Scientific’s $15 billion agreement to acquire Penumbra and Danaher’s agreement to acquire Masimo for $10 billion.
Business Trend Disruption: The IMF’s April 2026 World Economic Outlook notes that the outbreak of war in the Middle East in February 2026 has interrupted what had been a steady growth trajectory. Assuming a short-lived conflict,global growth is projected at 3.1% in 2026, a downward revision of 0.2 percentage points from its January forecast. Prior to the war, the agency had been preparing to raise its global growth outlook, reflecting continued economic momentum, a tech-investment boom, moderation in trade policy tensions, fiscal support in some countries and accommodating financial conditions. Global headline inflation is expected to rise from 4.1% in 2025 to 4.4% in 2026, before resuming its decline in 2027. Growth slowdown and an increase in inflation are expected to be more pronounced in emerging market and developing economies. The IMF apprehends that fostering adaptability, maintaining credible policy frameworks and reinforcing international cooperation are essential to navigating the current shock.
Zacks Industry Rank Indicates Dull Prospects The Zacks Medical Instruments industry’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates gloomy near-term prospects. The industry, housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #139, which places it in the bottom 43% of 243 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook. It is worth taking a look at the industry’s shareholder returns and current valuation first.
Industry Underperforms S&P 500 & Sector The industry has underperformed the Zacks S&P 500 composite and the sector in the past year.
The industry has declined 6.9% against the broader sector’s rise of 4.9%. The S&P 500 has returned 30.3% in a year.
1-Year Price Performance
Image Source: Zacks Investment Research
Industry's Current Valuation On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 24.00X compared with the broader industry’s 19.68X and the S&P 500’s 21.85X.
Over the past five years, the industry has traded as high as 41.40X, as low as 24.00X and at the median of 32.12X, as the charts show below.
Price-to-Earnings Forward 12 Months (F12M)
Image Source: Zacks Investment Research
Price-to-Earnings Forward 12 Months (F12M)
Image Source: Zacks Investment Research
3 Stocks to Buy Right Now Electromed: Electromed develops airway clearance products applying High Frequency Chest Wall Oscillation technologies in pulmonary care for patients.Its products are sold in both the homecare market and the hospital market for inpatient use.Electromed delivered its 14th consecutive quarter of year-over-year revenue and profit growth in the first quarter of 2026. With 86% of covered U.S. lives now under contract and manufacturing optimization complete, the company is well-positioned to capture the significant bronchiectasis market opportunity.
The Zacks Consensus Estimate for this Zacks Rank #1 (Strong Buy) company’s 2026 earnings per share (EPS) indicates a 41.2% rise over 2025. The consensus mark for 2026 revenues implies a 15.6% improvement. ELMD has an earnings yield of 3.1% against the industry’s negative 1% yield.
You can see the complete list of today's Zacks #1 Rank stocks here.
Price & Consensus: ELMD
Image Source: Zacks Investment Research
Globus Medical: Globus Medical develops advanced products and procedures to treat a variety of musculoskeletal conditions. The company’s 2023 merger with NuVasive enhanced its global commercial reach and operational capabilities, while the acquisition of Nevro in 2025 positioned it to alter the standard of care in the neuromodulation space. In first-quarter 2026, Globus Medical’s worldwide net sales climbed 27% year over year on a reported basis, while the bottom-line surged 64.7%.
The Zacks Consensus Estimate for this Zacks Rank #1 company’s 2026 EPS calls for 17.1% growth. The consensus mark for 2026 revenues indicates an 8.8% improvement. GMED has an earnings yield of 5.8% against the industry’s negative 1% yield.
Price & Consensus: GMED
Image Source: Zacks Investment Research
Intuitive Surgical: Intuitive Surgical is a renowned name in minimally invasive care and robotic-assisted surgery. The company’s technologies include the da Vinci surgical systems and the Ion endoluminal system. In the first quarter of 2026, worldwide combined procedures grew nearly 17% year over year, with strong performance in the United States and Europe. Intuitive Surgical is also investing in the data and digital infrastructure that underpins its longer-term innovation road map.
The Zacks Consensus Estimate for this Zacks Rank #2 (Buy) company’s 2026 EPS implies year-over-year growth of 16.5%. The consensus mark for 2026 revenues indicates an improvement of 16.5%. ISRG has an earnings yield of 2.4% against the industry’s negative 1% yield.
Price & Consensus: ISRG
Image Source: Zacks Investment Research
Globus Medical (GMED - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
As such, the Zacks rating upgrade for Globus Medical is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Globus Medical imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for Globus MedicalThis medical device company is expected to earn $4.74 per share for the fiscal year ending December 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for Globus Medical. Over the past three months, the Zacks Consensus Estimate for the company has increased 5.6%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Globus Medical to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.
That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.
However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.
Our proprietary system currently recommends Globus Medical (GMED - Free Report) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.
Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
While there are numerous reasons why the stock of this medical device company is a great growth pick right now, we have highlighted three of the most important factors below:
Earnings GrowthEarnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for Globus Medical is 17%, investors should actually focus on the projected growth. The company's EPS is expected to grow 19.1% this year, crushing the industry average, which calls for EPS growth of 10.7%.
Impressive Asset Utilization RatioAsset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric exhibits how efficiently a firm is utilizing its assets to generate sales.
Right now, Globus Medical has an S/TA ratio of 0.6, which means that the company gets $0.6 in sales for each dollar in assets. Comparing this to the industry average of 0.59, it can be said that the company is more efficient.
In addition to efficiency in generating sales, sales growth plays an important role. And Globus Medical looks attractive from a sales growth perspective as well. The company's sales are expected to grow 8.8% this year versus the industry average of 5.7%.
Promising Earnings Estimate RevisionsSuperiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for Globus Medical have been revising upward. The Zacks Consensus Estimate for the current year has surged 6.3% over the past month.
Bottom LineGlobus Medical has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #1 because of the positive earnings estimate revisions.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination indicates that Globus Medical is a potential outperformer and a solid choice for growth investors.
Key Takeaways GMED Q1 earnings jumped 64.7% as revenue and margins topped expectations on integration leverage.Globus Medical posted double-digit Spine growth and 30.4% Trauma growth across key products.GMED reaffirmed 2026 revenue guidance and raised EPS outlook as synergies expand margins. Globus Medical (GMED - Free Report) is leaning into its post-merger scale as it works to widen its share in musculoskeletal procedures. Management continues to emphasize share capture across core categories, supported by a portfolio that spans spine, orthopedics and enabling technologies.
First-quarter 2026 execution reinforced that setup. Profitability improved as integration initiatives flowed through margins, while category momentum in spine, trauma and enabling technologies remained intact.
GMED’s Post-Merger Setup in MusculoskeletalGlobus Medical is using the NuVasive combination to extend its reach across musculoskeletal solutions. The company now brings together engineering depth with a broader commercial footprint in training and surgeon relationships, positioning it to outpace market growth and convert scale into cash generation over time.
That scale advantage matters because the portfolio is wide. Musculoskeletal Solutions includes implantable devices, biologics, accessories and specialized instruments used across spinal, orthopedic and neurosurgical procedures, while Enabling Technologies adds imaging, navigation and robotic-assisted systems that support workflow and precision.
Globus Medical Q1 2026 Beat Shows Operating LeverageFirst-quarter 2026 results highlighted a cleaner integration picture. Adjusted earnings were $1.12 per share, up 64.7% year over year and ahead of the consensus estimate, while revenue of $759.9 million also beat expectations.
Profitability moved the right way as the company absorbed higher spending. Operating income rose 55.0% to $150.4 million, and operating margin expanded 358 basis points to 19.8%, reflecting operating leverage on higher volume. Gross margin also expanded 280 basis points to 66.4%.
Integration is showing up in the underlying margin profile. Management pointed to operating leverage as common systems roll out and production is brought in-house, with adjusted EBITDA margin at 32.3% and adjusted gross margin at 69.2% in the quarter.
The company also holds a solid track record of surpassing earnings estimates.
Image Source: Zacks Investment Research
GMED Spine and Trauma Gains Point to Share CaptureThe clearest signal in the quarter was the breadth of category wins. U.S. Spine posted its third straight quarter of 10% growth, with double-digit growth across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, posterior cervical and cervical plating.
Trauma also stood out. Revenue in the segment increased 30.4% on continued adoption of the core trauma line and the Precice limb lengthening portfolio, with ANTHEM Elbow exceeding expectations and prompting additional set shipments into the field in the second quarter.
Geography reinforced the message. U.S. revenue grew 25% to $604.9 million, while international revenue rose 35.6% to $155.0 million, supported by International Spine growth of 16.4% as reported. The combination suggests share capture is not confined to a single product line or region.
Globus Medical Robotics Pull-Through and New ClearancesEnabling Technologies remains a strategic lever because it can drive implant pull-through. Management described Excelsius GPS as supporting cross-selling as surgeons move toward a more integrated workflow. Enabling Technologies revenue increased 21.1% year over year in the first quarter.
The commercial model is evolving in a way that can deepen recurring revenue streams. Management noted a mix shift toward leases and rentals versus outright system sales. Over time, that approach can broaden the installed base and increase recurring revenues tied to implants, disposables, service and case coverage, even if capital revenue timing becomes less linear quarter to quarter.
Product cadence is also reinforcing the ecosystem. Early in the second quarter, the company received two FDA 510(k) clearances for a patient-specific lumbar interbody spacer system and patient-specific rods, both designed to integrate with the Excelsius suite and surgeon planning software.
GMED Guidance and Margin Targets Set 2026 MilestonesManagement reaffirmed full-year 2026 revenue guidance of $3.18-$3.22 billion. At the same time, it raised adjusted diluted earnings guidance to $4.70-$4.80, signalling confidence that margin expansion can outpace topline growth as synergies and manufacturing initiatives progress.
The margin roadmap remains central to the longer-term thesis. Management reiterated a long-term adjusted gross margin target in the mid-70s and expects 69%-70% for full-year 2026 as manufacturing and supply-chain initiatives advance. GMED also trades at a forward, 12-month earnings multiple of 16.94X, lower than its median and the industry average.
Image Source: Zacks Investment Research
For investors comparing options in medical devices, it is useful to note that large-cap peer Stryker Corporation (SYK - Free Report) currently carries a Zacks Rank #3 (Hold). Teleflex Incorporated (TFX - Free Report) , another medical technology name, also has a Zacks Rank #3 (Hold). GMED’s Zacks Rank #1 (Strong Buy) sets it apart on the Zacks framework.
You can see the complete list of today's Zacks #1 Rank stocks here.
Globus Medical Key Risks to Track Through 2026Higher input costs, compensation pressure and integration-related restructuring costs can create variability, especially when the long-term margin target leaves a limited buffer if costs move faster than pricing. Management also highlighted “new and enhanced” robotic competitors entering the market, a development that can raise discounting risk on enabling technology and related implants, while the lease-and-rental mix can make capital revenue less predictable.
Foreign exchange can materially affect reported results, and the Nevro integration is expected to remain lumpy as sales coverage is rebuilt and trading protocols tighten, with timing risk around when performance normalizes in the second half of 2026.
Key Takeaways TMDX is expanding its OCS platform and advancing kidney transplant development for long-term growth.TransMedics posted solid Q1 2026 results driven by strong OCS volume and logistics growth.TMDX gross margin fell 331 basis points as investments and logistics revenue weighed on results. TransMedics Group, Inc. (TMDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System (OCS) technology. The optimism, led by decent first-quarter 2026 results, is expected to contribute further. However, concerns due to gross margin pressure persist.
This Zacks Rank #3 (Hold) company has lost 42.3% in the year-to-date period compared with 17.7% decline in the industry. The S&P 500 has witnessed 10.3% growth in the said time frame.
The renowned organ transplant therapy provider has a market capitalization of $2.44 billion. TransMedics’ earnings yield of 2.63% compares favorably with the industry’s negative 3%. The company’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters, missed once, with the average surprise being 39.37%.
Image Source: Zacks Investment Research
Factors Favoring TMDX’s GrowthRobust Pipeline Supporting Growth: TransMedics continues to advance its long-term growth strategy through the development of next-generation OCS systems and expansion into new organ markets. The company is progressing its Gen 3.0 multi-organ platform for heart, lung and liver, featuring upgraded hardware, software and a redesigned perfusion system aimed at improving usability, reliability and operational efficiency while reducing supply chain complexity.
Clinical expansion efforts remain focused on the ENHANCE Heart and DENOVO Lung programs, with the newly introduced CHOPS active cooling device expected to support trial execution and potentially broaden the company’s commercial product portfolio over time. Beyond cardiothoracic transplants, management continues to position the kidney as a major long-term opportunity, with the OCS Kidney platform under active development and a U.S. IDE submission targeted for early 2027. The company is also enhancing its broader NOP ecosystem and digital infrastructure to improve scalability, workflow efficiency and coordination across transplant centers.
Strength in OCS Technology Driving Adoption: TransMedics’ OCS revolutionizes organ transplantation by replacing passive cold storage with a dynamic, physiologic approach that perfuses donor organs with warm, oxygenated, nutrient-rich blood. This innovation minimizes ischemic injury, allows real-time organ assessment and significantly increases the viability of organs, especially hearts and lungs, donated after circulatory death, that would otherwise go unused.
As the only FDA-approved, portable platform offering warm perfusion for heart, lung and liver transplants, the OCS standardizes care, reduces post-transplant complications and sets a new clinical benchmark in organ preservation. This positions TransMedics as a leader in the multi-billion-dollar transplant market with limited competition.
Decent Q1 Results: TransMedics delivered solid first-quarter 2026 results, driven by strong OCS case volume growth, expanding clinical adoption and continued momentum in logistics services. Growth was supported by strong liver performance, steady heart adoption and higher aviation fleet utilization within the integrated National OCS Program (NOP).
While profitability remained pressured by elevated investments in expansion and clinical programs, the company continues to execute well on its long-term growth strategy. Management remains focused on advancing the ENHANCE Heart and DENOVO Lung programs, expanding internationally and developing the OCS Kidney platform, which represents a significant long-term growth opportunity.
A Factor That Can Offset the Gains for TMDXGross Margin Under Pressure: TransMedics’ gross margin remained under pressure in the first quarter of 2026 as the company continued scaling its integrated NOP infrastructure and investing aggressively in future growth initiatives. Gross margin came in at approximately 58%, down 331 basis points year over year, primarily due to higher internal supply chain activity tied to NOP inventory replenishment, investments supporting the ENHANCE and DENOVO clinical programs and continued expansion of the NOP network.
The growing contribution from lower-margin logistics and service revenues also weighed on blended margin performance. Management noted that certain one-time items further pressured margins during the quarter. The company expects near-term gross margins to remain range-bound around current levels as it continues investing in international expansion, technology upgrades and logistics infrastructure before scale efficiencies and operating leverage more meaningfully materialize.
Estimate TrendTransMedics is witnessing a negative earnings estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings moved 61 cents south to $1.85 per share.
The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $184.6 million, indicating a 17.3% improvement from the year-ago quarter’s reported number.
Key PicksSome better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted earnings per share of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.
Key Takeaways GMED is shifting robotics deals to leases and rentals to expand recurring revenue streams.Excelsius GPS adoption and new FDA-cleared implants support GMED's integrated workflow expansion.GMED posted 27% Q1 revenue growth and raised 2026 adjusted EPS guidance to $4.70-$4.80. Globus Medical (GMED - Free Report) is changing how it monetizes surgical robotics. Management is steering enabling technologies toward leases and rentals instead of outright sales. That can lower upfront revenue recognition and make quarterly results less predictable. The aim is to widen the installed base and grow recurring revenue tied to implants, disposables, service and case coverage.
GMED sports a Zacks Rank #1 (Strong Buy). In the past year, the stock has climbed 39.3%, outperforming its industry’s 7.8% fall.
Image Source: Zacks Investment Research
GMED’s Shift to Leases and Rentals Changes the ModelThe shift is happening alongside strong top-line momentum. In the first quarter of 2026, revenue rose 27% year over year to $759.9 million, while base business sales excluding Nevro increased 13.2%. Those results suggest the company can push a new commercialization model without losing demand.
Management described continued deal activity in enabling technologies, but with a pipeline shifting toward leases and rentals. A sale recognizes more revenue upfront, while a lease spreads it over time. That is why capital revenue timing can become less linear even when demand is healthy.
Strategically, the company is trading cleaner quarterly optics for a larger footprint. More systems in the field can support recurring streams tied to implants, disposables, service and case coverage, turning placements into a gateway for downstream pull-through.
Globus Medical Builds a Workflow Around Excelsius GPSThe commercial logic centers on Excelsius GPS. Management said the platform supports implant pull-through and cross-selling as surgeons adopt a more integrated workflow. The objective is to make the company’s tools part of repeatable steps that favor the broader portfolio.
In the first quarter of 2026, Enabling Technologies revenue increased 21.1% year over year, a near-term indicator that adoption is building. If the installed base expands through leases and rentals, the workflow linkage to ongoing procedures becomes the value driver.
GMED Patient-Specific Implants Add a New DifferentiatorTwo early second-quarter Food and Drug Administration 510(k) clearances add to the platform thesis. The company received clearance for a patient-specific lumbar interbody spacer system and for patient-specific rods, both designed to integrate with the Excelsius suite and surgeon planning software.
That integration reinforces the roadmap of linking planning, enabling technology and implants into a single workflow. Patient-specific products can deepen account relationships and lift procedure-level pull-through over time.
Globus Medical Synergies Aim to Lift Margins Over TimeNuVasive integration is positioned to provide operating leverage through common systems and more in-house production. As of Dec. 31, 2025, the company reported $200 million of NuVasive synergies, nearly a year ahead of schedule. Additional benefits are expected as international integrations are finalized in the back half of 2026.
Profitability is already moving in that direction. Adjusted gross margin was 69.2%, and adjusted EBITDA margin was 32.3% in the first quarter of 2026. Management reiterated a long-term adjusted gross margin target in the mid-70s and expects 69% to 70% for full-year 2026. It also raised full-year 2026 adjusted earnings per share guidance to $4.70-$4.80 while reaffirming revenue guidance of $3.18-$3.22 billion.
In terms of valuation, GMED trades at a forward, 12-month price/earnings (P/E) of 16.92x, lower than its median and industry average.
Image Source: Zacks Investment Research
GMED Nevro Rebuild Is a Wild Card for 2026 ResultsNevro remains the largest swing factor. In the first quarter of 2026, Nevro contributed $82.7 million of revenue, down $17.1 million from the prior quarter. Management expects lumpiness in the first 24 months while recruiting and retraining the sales organization, targeting a return to a more historical run-rate late in the second half of 2026.
Until that rebuild stabilizes, consolidated growth can look uneven even if the core musculoskeletal franchise is performing well. Investors will want to see sales coverage rebuild without disrupting customer behavior as trading protocols tighten.
Globus Medical Watchlist for Risks and Timing LumpsThe practical watchlist starts with quarterly variability tied to the enabling-technology mix shift. Leases and rentals can broaden adoption, but they reduce upfront recognition versus outright sales and can make comparisons less predictable.
Competition is the second risk. Management noted that new and enhanced robotic competitors are entering the market, which could drive discounting on enabling technology and related implants to protect account access. Stryker Corporation (SYK - Free Report) and Teleflex Incorporated (TFX - Free Report) both hold a Zacks Rank #3 (Hold), underscoring how quickly pricing pressure can rise when peers stay aggressive. You can see the complete list of today's Zacks #1 Rank stocks here.
Margin sensitivity and foreign exchange volatility round out the list. The long-term gross margin objective in the mid-70s leaves a limited cushion if cost inflation rises faster than pricing. International net sales were $155.0 million in the first quarter of 2026, and a $2.1 million foreign currency transaction loss affected other income and expenses, showing how currency can move reported results.
NEW YORK, June 1, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Globus Medical, Inc. (NYSE: GMED) on behalf of the company's shareholders. The investigation seeks to determine whether Globus Medical's directors breached their fiduciary duties in connection with recent corporate actions.
If you are a shareholder of Globus Medical and are interested in obtaining additional information about your rights and options, please visit us at: https://pjlfirm.com/globus-medical-inc/
You may also contact Robert H. Lefkowitz, Esq. either via email at [email protected] or by telephone at 212-725-1000. One of our attorneys will personally speak with you about the case at no cost or obligation.
Purcell & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, please visit https://pjlfirm.com. Attorney advertising. Prior results do not guarantee a similar outcome.
Key Takeaways GMED ended Q1 2026 debt-free with about $560.9M cash and $68.9M in short-term marketable securities. Globus Medical generated $202.4M in Q1 operating cash flow, supporting growth investments. GMED had $390M left under its share repurchase authorization as of March 31, 2026. Globus Medical (GMED - Free Report) maintains a strong balance sheet and liquidity position, providing significant financial flexibility to execute its growth strategy. As of the end of the first quarter of 2026, the company held approximately $560.9 million in cash and $68.9 million in short-term marketable securities.
GMED remains debt-free, preserving its ability to invest in research and development, expand its sales force and enhance manufacturing capacity without relying on external financing. The absence of debt also lowers financial risk and eliminates interest expense obligations, enabling management to direct capital toward higher-return growth initiatives.
The company's liquidity position is also being strengthened through internally generated cash flow. During the first quarter, it generated $202.4 million in operating cash flow, reflecting the strong profitability.
The company had $390 million remaining under its share repurchase authorization as of March 31, 2026, providing additional flexibility to return capital to shareholders while helping offset share dilution.
Globus Medical's debt-free balance sheet, nearly $630 million in highly liquid assets and robust operating cash flow position the company well to execute its growth strategy. These financial strengths could serve as important drivers of future market-share gains and margin expansion.
Peer UpdateZimmer Biomet (ZBH - Free Report) ended first-quarter 2026 with cash and cash equivalents of $424.2 million. Debt remained elevated, with total debt of $7.47 billion and net debt of $7.05 billion. The current portion of long-term debt increased to $1.18 billion, reflecting upcoming maturities.
ZBH continued returning capital to shareholders through $250 million of share repurchases during the quarter, a move that may reduce near-term balance-sheet flexibility as the company funds integration efforts and commercial investments. At the end of the first quarter, Zimmer Biomet's debt-to-capital ratio stood at a moderately elevated 37.1%.
Teleflex (TFX - Free Report) exited the first quarter of 2026 with cash and cash equivalents of $309.4 million. TFX’s short-term debt was $103 million, much lower than the cash level. However, long-term borrowings in the quarter were $2.51 billion. Teleflex’s debt-to-capital ratio is 45.9% for the first quarter, implying a relatively high leverage profile that could limit financial flexibility.
GMED’s Stock Price PerformanceOver the past year, Tempus’ shares have surged 30.7%, outperforming the industry’s 6.5% decline.
Image Source: Zacks Investment Research
GMED’s ValuationGMED currently trades at a forward 12-month Price-to-Sales (P/S) of 3.21X compared with the industry median of 4.52X.
Image Source: Zacks Investment Research
GMED Stock Estimate TrendIn the past 30 days, Tempus AI's EPS estimate for 2026 has moved north to $4.74.
Image Source: Zacks Investment Research
GMED currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Globus Medical (GMED - Free Report) Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across 65 counties worldwide and sells through a mix of direct sales representatives and independent distributors.
GMED is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.88; value investors should take notice.
For fiscal 2026, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.28 to $4.74 per share. GMED boasts an average earnings surprise of +26.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, GMED should be on investors' short list.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Shares of Globus Medical (GMED - Free Report) have gained 2.6% over the past four weeks to close the last trading session at $80, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $111.08 indicates a potential upside of 38.9%.
The mean estimate comprises 12 short-term price targets with a standard deviation of $11.15. While the lowest estimate of $87.00 indicates an 8.8% increase from the current price level, the most optimistic analyst expects the stock to surge 53.8% to reach $123.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
However, an impressive consensus price target is not the only factor that indicates a potential upside in GMED. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in GMEDThere has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 6.3%, as four estimates have moved higher compared to no negative revision.
Moreover, GMED currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much GMED could gain, the direction of price movement it implies does appear to be a good guide.
Key Takeaways GMED Q1 2026 worldwide net sales rose 27%, while base business sales increased 13.2%. GMED posted a third straight quarter of 10% U.S. Spine growth; International Spine grew 16.4%. GMED trauma revenues climbed 30.4%, driven by core trauma adoption and the Precice portfolio. According to a report by Market Research Intellect, the musculoskeletal system market was valued at $15.6 billion in 2025 and is projected to witness a CAGR of 11.96% from 2026 to 2033, reaching an estimated $38.52 billion by 2033. This creates a favorable setup for Globus Medical’s (GMED - Free Report) broad implant portfolio across spine and orthopedics.
In the first quarter of 2026, worldwide net sales rose 27% year over year, while base business sales, excluding Nevro, increased 13.2%.
U.S. Spine marked its third straight quarter of 10% growth, with double-digit growth cited across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, posterior cervical and cervical plating. International Spine grew 16.4% as reported in the first quarter.
Trauma revenues increased 30.4% in the quarter, aided by continued adoption of the core trauma line and the Precice limb lengthening portfolio, with ANTHEM Elbow continuing to exceed expectations, prompting the company to ship additional sets to the field in the second quarter.
Peer UpdateZimmer Biomet (ZBH - Free Report) continues to see stable demand across the global musculoskeletal market, supported by procedure volumes and ongoing new product adoption. While pricing remains a key swing factor, the first-quarter 2026 performance suggests end markets have remained resilient.
In the first quarter, large joints sales remained positive. Hips net sales were up 3.2% organically and total Knees net sales increased 1.8% organically. International net sales grew 4.2% at constant currency and 2.5% organically, reflecting healthy demand trends despite varying performance across countries.
Stryker’s (SYK - Free Report) long-term growth potential is underpinned by a vast and expanding total addressable market across its Orthopaedics business. Mako remains central to Stryker’s orthopaedics strategy and supports recurring pull-through from implants, consumables, and service.
In the first quarter of 2026, the company reported a record first-quarter performance for Mako installations in both the United States and international markets, supported by high and rising utilization rates. Management also highlighted positive surgeon feedback for Mako Shoulder and expects a full launch of Mako 4 in mid-2026. The launch is anticipated to broaden the range of procedures performed on the platform and further support utilization growth.
GMED’s Stock Price PerformanceOver the past year, GMED shares have surged 33.5%, outperforming the industry’s 6.0% decline.
Image Source: Zacks Investment Research
GMED’s ValuationGMED currently trades at a forward 12-month Price-to-Sales (P/S) of 3.30X compared with the industry median of 4.76X.
Image Source: Zacks Investment Research
GMED Stock Estimate TrendIn the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
Image Source: Zacks Investment Research
GMED currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to questions received from its European Notified Body, GMED, following the successful completion of the Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED as part of the MDR conformity assessment process for the Lumee® Oxygen Platform.
The response package included updates across multiple aspects of the MDR submission, including technical documentation, quality system evidence, clinical evaluation activities, and supporting validation information.
The submission represents an important step in the Company's ongoing efforts to obtain CE Mark certification for the Lumee Oxygen Platform and supports Profusa's broader strategy to commercialize the technology in Europe.
"Submitting our responses to GMED marks another meaningful milestone in the CE Mark review process," said Ben Hwang, Ph.D., Profusa’s Chairman and Chief Executive Officer. "We appreciate GMED's continued engagement throughout the assessment and remain committed to working collaboratively with the agency as it completes its review. We believe the Lumee Oxygen Platform has the potential to address a significant unmet need by providing clinicians with continuous, real-time tissue oxygen monitoring, and we look forward to advancing toward European commercialization."
The CE Mark review process remains ongoing, and there can be no assurance regarding the timing or outcome of GMED's assessment. Profusa will continue to support the review process and provide updates on material regulatory milestones as appropriate.
About the Lumee® Oxygen Platform
The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through Profusa's proprietary tissue-integrated biosensor technology. The platform is intended to provide clinicians with objective tissue perfusion data that may support treatment decision-making and patient monitoring.
About Profusa
Based in Berkeley, CA, Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa, including statements regarding the proposed acquisition, the anticipated launch of PanOmics DX™, and Profusa’s strategic plans. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements including, without limitation, risks related to the Company's planned European and U.S. product launches, the risk that such product launches may not result in revenue at the levels anticipated, the risk that customer demand may be less than expected, and risks relating to the Company’s withdrawal of the Registration Statement and conducting a smaller offering of its securities. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described more fully in the Company's public filings made by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”), or in a transaction exempt from the registration requirements of the Securities Act.
Contacts
Investor and Media Contacts
email: [email protected]
phone: 1 (212) 655-0924
